Nebenwirkungen · Xtandi
Xtandi - 40 mg film-coated tablets Xtandi - 80 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 40
HOS-127948 · Präparat HOS-096479
Gynaecomastia In the EMBARK study, gynaecomastia (all grades) was observed in 31 of 353 patients (8.8%) who were treated with enzalutamide plus leuprolide and 163 of 354 patients (46%) who were treated with enzalutamide as monotherapy. Grade 3 or higher gynaecomastia was not observed in any patients who were treated with enzalutamide plus leuprolide, and was observed in 1 patient (0.3%) treated with placebo plus leuprolide and 3 patients (0.8%) who were treated with enzalutamide as monotherapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-29T10:07:00Z · SHA-256 2bf5e532360d917a40a8717a4c2398563991ca5e2d824233a2adf92bb006bfb9 · Passage 6f667af4cc6a1bd711aa7d2ff26a685f275b5bc1aa2266ab63fb01f2f9664d57 · Zeichen 6454–6953 im Abschnitt